Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 3/2015

01-09-2015 | Original Article

Brain metastasis from colorectal carcinoma: a single cancer centre experience

Authors: R. Tevlin, J. O. Larkin, J. M. Hyland, P. R. O’Connell, D. C. Winter

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2015

Login to get access

Abstract

Purpose

Brain metastases (BM) from colorectal cancer (CRC) are rare. As survival increases in patients with metastatic CRC, it is hypothesised that new metastatic patterns will emerge: for instance, as CRC with limited metastatic involvement of the liver and lung can now be successfully resected, we propose that sites, previously rarely involved in metastatic spread, will become more common. The objective of this study was to describe the experience with BM from CRC in a single cancer centre.

Methods

A prospectively compiled database (1988–2012) of patients with CRC treated in a tertiary referral hospital was retrospectively examined. Patients with a histological diagnosis of CRC and radiologically documented BM were included. Clinical information (including patient demographics, primary and metastatic disease factors) was obtained from medical records.

Results

Eleven patients (0.3 % of 4219 patients) were identified (8 male, 3 female). The median age at CRC diagnosis was 70 years (range 55–80 years) while the median age at diagnosis of BM was 73 years (range 56–83 years). Three patients diagnosed with synchronous metastases underwent palliative treatment while eight patients had undergone surgical resection of the primary tumour with curative intent a median of 24 months (range 0–48 months) prior to diagnosis of BM. 10/11 patients were symptomatic at diagnosis of BM. All were diagnosed using computed tomography and managed palliatively. The cerebellum was most the frequently involved site. The median overall survival time following diagnosis of BM was 2.5 months (range 2–9 months). Notably, 8/11 patients were diagnosed in the latter 8 years of the study period (between 2004 and 2012).

Conclusion

With increased survival, improved systemic therapy and aggressive approaches to surgical management of “classical” metastases from CRC, it is likely that a changing pattern of metastases will emerge. As survival rates increase, we propose that metastatic sites, which were previously considered rare (e.g. brain), will now become more common and thus, surgeons must recognise pertinent symptomatology.
Literature
3.
go back to reference South and West Cancer Intelligence Unit (2000) Wessex colorectal cancer audit: final report, 5 year outcomes. South and West Cancer Intelligence Unit, Wessex South and West Cancer Intelligence Unit (2000) Wessex colorectal cancer audit: final report, 5 year outcomes. South and West Cancer Intelligence Unit, Wessex
4.
go back to reference Wronski M, Arbit E (1999) Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 85(8):1677–1685CrossRefPubMed Wronski M, Arbit E (1999) Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 85(8):1677–1685CrossRefPubMed
5.
go back to reference Go PH et al (2011) Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117(16):3630–3640CrossRefPubMed Go PH et al (2011) Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117(16):3630–3640CrossRefPubMed
6.
go back to reference Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1):5–14CrossRefPubMed Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1):5–14CrossRefPubMed
7.
go back to reference Sperduto PW et al (2010) Diagnosis-specific prognostic factors, indexes and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77:655–661CrossRefPubMed Sperduto PW et al (2010) Diagnosis-specific prognostic factors, indexes and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77:655–661CrossRefPubMed
8.
go back to reference Tabouret E et al (2012) Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 32(11):4655–4662PubMed Tabouret E et al (2012) Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 32(11):4655–4662PubMed
9.
go back to reference Damiens K et al (2012) Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol 19(5):254–258PubMedCentralCrossRefPubMed Damiens K et al (2012) Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol 19(5):254–258PubMedCentralCrossRefPubMed
10.
go back to reference Rees M et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135CrossRefPubMed Rees M et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135CrossRefPubMed
11.
go back to reference Demmy TL, Dunn KB (2007) Surgical and nonsurgical therapy for lung metastasis: indications and outcomes. Surg Oncol Clin N Am 16(3):579–605 (ix)CrossRefPubMed Demmy TL, Dunn KB (2007) Surgical and nonsurgical therapy for lung metastasis: indications and outcomes. Surg Oncol Clin N Am 16(3):579–605 (ix)CrossRefPubMed
12.
go back to reference Grothey A et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209–1214CrossRefPubMed Grothey A et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209–1214CrossRefPubMed
13.
go back to reference O’Neill BP et al (2003) A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55(5):1169–1176CrossRefPubMed O’Neill BP et al (2003) A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55(5):1169–1176CrossRefPubMed
14.
go back to reference Jung M et al (2011) Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 101(1):49–55CrossRefPubMed Jung M et al (2011) Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 101(1):49–55CrossRefPubMed
15.
go back to reference Onaitis MW et al (2009) Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87(6):1684–1688CrossRefPubMed Onaitis MW et al (2009) Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87(6):1684–1688CrossRefPubMed
16.
go back to reference House MG et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210(5):744–752 (752–755)CrossRefPubMed House MG et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210(5):744–752 (752–755)CrossRefPubMed
17.
go back to reference Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580CrossRefPubMed Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580CrossRefPubMed
18.
go back to reference Cardona K et al (2013) Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. Ann Surg Oncol 20(1):148–154CrossRefPubMed Cardona K et al (2013) Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. Ann Surg Oncol 20(1):148–154CrossRefPubMed
20.
go back to reference Kye BH et al (2012) Brain metastases from colorectal cancer: the role of surgical resection in selected patients. Colorectal Dis 14(7):e378–e385CrossRefPubMed Kye BH et al (2012) Brain metastases from colorectal cancer: the role of surgical resection in selected patients. Colorectal Dis 14(7):e378–e385CrossRefPubMed
21.
go back to reference Sundermeyer ML et al (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113CrossRefPubMed Sundermeyer ML et al (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113CrossRefPubMed
22.
go back to reference Farnell GF et al (1996) Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78(4):711–716CrossRefPubMed Farnell GF et al (1996) Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78(4):711–716CrossRefPubMed
Metadata
Title
Brain metastasis from colorectal carcinoma: a single cancer centre experience
Authors
R. Tevlin
J. O. Larkin
J. M. Hyland
P. R. O’Connell
D. C. Winter
Publication date
01-09-2015
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 3/2015
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-015-1272-y

Other articles of this Issue 3/2015

Irish Journal of Medical Science (1971 -) 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.